Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro and Ex Vivo Applications
Wednesday, April 25, 2018: 10 am ET
Thursday, April 26, 2018: 2 pm ET
The development of novel cancer therapies to take into the clinic requires significant evaluation of efficacy and activity at the preclinical level. With 95% of drugs failing clinical trials, there is a critical need for a more robust approach to these preclinical studies. A better understanding of how drugs are evaluated in vitro, ex vivo, and in vivo allows the individual advantages and limitations presented by each study type to be leveraged throughout this complex process.
The use of Patient-Derived Xenograft (PDX) models has addressed the need for a more translational in vivo platform, and has proven to be a predictive model for human population heterogeneity. Establishing methods to back translate these unique models to in vitro and ex vivo studies, by deriving cell lines and establishing 3D culture capabilities, enables researchers to take full advantage of the translational capabilities of PDX models, facilitating a more confident transition to the clinic.
Attend This Webinar To Discover:
- The importance of utilizing highly translational cancer models such as PDX across the full spectrum of preclinical research
- The benefits and limitations of in vitro, ex vivo, and in vivo PDX study types and how they can be leveraged together for more translational preclinical studies
- How this wide variety of PDX platforms can be used for immuno-oncology studies
About The Presenter:
Dr. John MacDougall, Crown Bioscience, is trained as a Cancer Biologist, having received his PhD from the Department of Medical Biophysics at The University of Toronto and a Susan G. Komen Foundation Post-Doctoral Fellowship in the Department of Cell Biology at Vanderbilt University. Following his formal training, John joined the Northwestern Ontario Regional Cancer Center as a Career Scientist and as an adjunct Professor in the Department of Biology at Lakehead University.
In 2000, John began his career in oncology drug discovery and has held a variety of roles across the discovery spectrum - Target ID through in vitro and in vivo pharmacology and toxicology. Through the companies he has represented (CuraGen, Serono, Infinity, ImmuneXcite, Aura) John has worked on numerous drug modalities, including small molecules, antibody-drug conjugates and nanoparticles, that have advanced through preclinical studies into clinical trials.